GlassScriptPhysician profile
Anthony Chahin
NPI 1891236147
$1,792.32
in general payments reported to CMS, 2019-2025
22 companies · $676 in 2025
The $676 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $266 · 2024: $849 · 2025: $676.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,792.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,792.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $315.73 | 2023-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $273.06 | 2023-2025 | Fasenra, Tezspire, Airsupra |
| Grifols USA, LLC | $216.82 | 2023-2025 | Prolastin-C Liquid |
| Regeneron Healthcare Solutions, INC. | $185.80 | 2023-2025 | Dupixent |
| Amgen INC. | $121.21 | 2024-2025 | Tezspire, Tavneos |
| Insmed, INC. | $86.64 | 2024-2025 | Arikayce |
| Harmony Biosciences LLC | $76.31 | 2024 | |
| Baxter Healthcare | $65.11 | 2024-2025 | Hillrom - Vest System Model 105 Home Care, Hillrom - Volara System |
| Axsome Therapeutics, INC. | $53.22 | 2023-2024 | Sunosi |
| Electromed, INC. | $53.15 | 2024-2025 | Smartvest |
| Viatris Specialty LLC | $49.59 | 2025 | Yupelri |
| Vifor Pharma, INC. | $43.38 | 2024-2025 | Zemaira |
| Takeda Pharmaceuticals U.S.A., INC. | $39.31 | 2025 | Glassia |
| Mallinckrodt Hospital Products INC. | $39.00 | 2023 | Acthar |
| Mylan Specialty L.P. | $30.62 | 2024 | Yupelri |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $26.46 | 2024 | |
| United Therapeutics Corporation | $24.64 | 2023 | Tyvaso |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.89 | 2023 | Stiolto Respimat |
| Inspire Medical Systems, INC. | $20.78 | 2025 | Inspire |
| Lilly USA, LLC | $18.54 | 2025 | Zepbound |
| Merck Sharp & Dohme LLC | $16.61 | 2024 | Recarbrio, Zerbaxa |
| Abbvie INC. | $15.45 | 2023 | Teflaro |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Chahin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.